These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21781257)

  • 21. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.
    Lillicrap D
    Blood; 2013 Nov; 122(23):3735-40. PubMed ID: 24065240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
    Hillery CA; Mancuso DJ; Evan Sadler J; Ponder JW; Jozwiak MA; Christopherson PA; Cox Gill J; Paul Scott J; Montgomery RR
    Blood; 1998 Mar; 91(5):1572-81. PubMed ID: 9473222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay.
    Dean JA; Blanchette VS; Carcao MD; Stain AM; Sparling CR; Siekmann J; Turecek PL; Lillicrap D; Rand ML
    Thromb Haemost; 2000 Sep; 84(3):401-9. PubMed ID: 11019962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. von Willebrand factor: biological function and molecular defects.
    Perutelli P; Biglino P; Mori PG
    Pediatr Hematol Oncol; 1997; 14(6):499-512. PubMed ID: 9383803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New advances in the diagnosis of von Willebrand disease.
    Sharma R; Haberichter SL
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):596-600. PubMed ID: 31808831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rethinking the diagnosis of von Willebrand disease.
    Favaloro EJ
    Thromb Res; 2011 Jan; 127 Suppl 2():S17-21. PubMed ID: 21193108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Von Willebrand factor and Von Willebrand disease].
    Verhezen PW; Beckers EA; Henskens YM
    Ned Tijdschr Geneeskd; 2014; 158():A6885. PubMed ID: 24800797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis and management of von Willebrand disease in Australia.
    Favaloro EJ; Bonar R; Favaloro J; Koutts J
    Semin Thromb Hemost; 2011 Jul; 37(5):542-54. PubMed ID: 22102198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type 2M von Willebrand disease variant characterized by abnormal von willebrand factor multimerization.
    Casonato A; Pontara E; Sartorello F; Bertomoro A; Durante C; Girolami A
    J Lab Clin Med; 2001 Jan; 137(1):70-6. PubMed ID: 11150026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Von Willebrand disease type 2M: Correlation between genotype and phenotype.
    Maas DPMSM; Atiq F; Blijlevens NMA; Brons PPT; Krouwel S; Laros-van Gorkom BAP; Leebeek FWG; Nieuwenhuizen L; Schoormans SCM; Simons A; Meijer D; van Heerde WL; Schols SEM
    J Thromb Haemost; 2022 Feb; 20(2):316-327. PubMed ID: 34758185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosing von Willebrand disease: a short history of laboratory milestones and innovations, plus current status, challenges, and solutions.
    Favaloro EJ
    Semin Thromb Hemost; 2014 Jul; 40(5):551-70. PubMed ID: 24978322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autosomal dominant von Willebrand disease type 2M.
    Hermans C; Batlle J
    Acta Haematol; 2009; 121(2-3):139-44. PubMed ID: 19506360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Laboratory Testing for Von Willebrand Factor Multimers.
    Oliver S; Lau KKE; Chapman K; Favaloro EJ
    Methods Mol Biol; 2017; 1646():495-511. PubMed ID: 28804850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The molecular analysis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organisation Haemophilia Genetics Laboratory Network.
    Keeney S; Bowen D; Cumming A; Enayat S; Goodeve A; Hill M;
    Haemophilia; 2008 Sep; 14(5):1099-111. PubMed ID: 18637846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current and emerging approaches for assessing von Willebrand disease in 2016.
    Federici AB
    Int J Lab Hematol; 2016 May; 38 Suppl 1():41-9. PubMed ID: 27426859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies.
    James PD; Lillicrap D
    Am J Hematol; 2012 May; 87 Suppl 1(0 1):S4-11. PubMed ID: 22389132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.
    Castaman G; Federici AB; Rodeghiero F; Mannucci PM
    Haematologica; 2003 Jan; 88(1):94-108. PubMed ID: 12551832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for the Misfolding of the A1 Domain within Multimeric von Willebrand Factor in Type 2 von Willebrand Disease.
    Tischer A; Brehm MA; Machha VR; Moon-Tasson L; Benson LM; Nelton KJ; Leger RR; Obser T; Martinez-Vargas M; Whitten ST; Chen D; Pruthi RK; Bergen HR; Cruz MA; Schneppenheim R; Auton M
    J Mol Biol; 2020 Jan; 432(2):305-323. PubMed ID: 31628947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High resolution multimer analysis and the PFA-100 platelet function analyser can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level.
    Weiss DR; Strasser EF; Ringwald J; Zimmermann R; Eckstein R
    Clin Lab; 2012; 58(11-12):1203-9. PubMed ID: 23289190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.